📰 Nasdaq Pcvx News
Page 4 - Nasdaq Pcvx News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Nasdaq Pcvx. Real-time updates on events, politics, business and more.
September 18, 2023
Shares of Vaxcyte, Inc. (NASDAQ:PCVX – Get Free Report) have received an average rating of “Buy” from the six analysts that are currently covering the firm, MarketBeat Ratings reports. Six investment analysts have rated the stock with a buy rating. The average 1-year target price among brokers that have issued a report on the stock […]
August 30, 2023
Vaxcyte (NASDAQ:PCVX – Get Free Report) and Ginkgo Bioworks (NYSE:DNA – Get Free Report) are both mid-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, institutional ownership, valuation, risk and profitability. Analyst Recommendations This is a summary of recent […]
August 16, 2023
Vaxcyte, Inc. (NASDAQ:PCVX – Free Report) – Analysts at Cantor Fitzgerald lifted their FY2023 EPS estimates for shares of Vaxcyte in a report released on Wednesday, August 9th. Cantor Fitzgerald analyst L. Chen now expects that the company will post earnings per share of ($3.05) for the year, up from their prior estimate of ($3.15). […]
August 16, 2023
Vaxcyte, Inc. (NASDAQ:PCVX – Free Report) – Cantor Fitzgerald increased their FY2023 EPS estimates for shares of Vaxcyte in a report released on Wednesday, August 9th. Cantor Fitzgerald analyst L. Chen now forecasts that the company will post earnings per share of ($3.05) for the year, up from their previous forecast of ($3.15). The consensus […]
August 16, 2023
Vaxcyte, Inc. (NASDAQ:PCVX – Free Report) – Leerink Partnrs cut their Q3 2023 EPS estimates for Vaxcyte in a research report issued on Sunday, August 13th. Leerink Partnrs analyst D. Risinger now anticipates that the company will earn ($0.73) per share for the quarter, down from their previous estimate of ($0.70). The consensus estimate for […]
August 10, 2023
Vaxcyte (NASDAQ:PCVX – Get Free Report)‘s stock had its “buy” rating restated by investment analysts at Needham & Company LLC in a note issued to investors on Wednesday, Benzinga reports. They presently have a $58.00 price target on the stock. Needham & Company LLC’s target price would suggest a potential upside of 22.80% from the […]
August 8, 2023
-- Advanced Ongoing VAX-24 Phase 2 Infant Study to Second Stage, Dosing First New Participants in July 2023; Topline Data from Primary Immunization Series...
July 11, 2023
Vaxcyte, Inc. (NASDAQ:PCVX – Get Free Report)’s stock price gapped down before the market opened on Tuesday . The stock had previously closed at $47.61, but opened at $46.29. Vaxcyte shares last traded at $47.31, with a volume of 25,746 shares trading hands. Wall Street Analyst Weigh In A number of research analysts have weighed […]
July 3, 2023
Vaxcyte (NASDAQ:PCVX – Free Report) and Titan Pharmaceuticals (NASDAQ:TTNP – Free Report) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, risk, dividends, valuation, earnings, analyst recommendations and profitability. Analyst Ratings This is a summary of recent recommendations for Vaxcyte […]
June 5, 2023
Vivo Capital LLC grew its position in Vaxcyte, Inc. (NASDAQ:PCVX – Get Rating) by 43.3% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 579,508 shares of the company’s stock after purchasing an additional 175,000 shares during the quarter. Vaxcyte makes up 3.2% of […]